Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
IMPRoving Outcomes in Vascular DisEase - Aortic Dissection
NCT06087029 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.
Conditions Studied
Interventions
- PROCEDURE TEVAR
- OTHER Guideline directed medical therapy and surveillance of dissection
Study Locations (20)
California
- Memorial Care Long Beach Medical Center — Long Beach
- Keck Medical Center of USC — Los Angeles
- University of California San Diego — San Diego
- University of California — San Francisco
- Stanford University Medical Center — Stanford
Illinois
- Northwestern University — Chicago
- The University of Chicago — Chicago
- Southern Illinois University School of Medicine — Springfield
Colorado
- University of Colorado Denver — Aurora
- Memorial Hospital Central — Colorado Springs
Connecticut
- Hartford Hospital — Hartford
- Yale University — New Haven
Florida
- University of Florida Health — Gainesville
- Tampa General Hospital — Tampa
Alabama
- University of Alabama at Birmingham — Birmingham
Arizona
- Honorhealth — Phoenix
Indiana
- Indiana University Methodist Hospital — Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2024-04-14 |
| Est. Completion | 2030-06-30 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06087029
The ClinicalTrials.gov registry entry for NCT06087029 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,129 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Type B Aortic Dissection appearing as the primary indexed condition, and to 2 interventions — of which TEVAR is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06087029 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Illinois, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06087029 about?
NCT06087029 is a clinical study titled "IMPRoving Outcomes in Vascular DisEase - Aortic Dissection". The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for det...
What is the current status of trial NCT06087029?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,100 participants. The study started on 2024-04-14. Estimated completion is 2030-06-30.
What conditions does trial NCT06087029 study?
This clinical trial studies the following conditions: Type B Aortic Dissection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06087029?
The interventions under investigation include: TEVAR (PROCEDURE), Guideline directed medical therapy and surveillance of dissection (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06087029?
This trial is sponsored by Duke University, which has 1,129 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06087029 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.